AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11246243 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume ventriculography (15 mL/sec for 1 sec)
Number of subjects: 102
Study 11246243 — intervention group
Group type: COMPARATOR
Intervention: Standard-volume ventriculography (15 mL/sec for 3 sec)
Number of subjects: 102
Study 11246243 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume ventriculography
Number of subjects: 102
Study 11246243 — intervention group
Group type: COMPARATOR
Intervention: Standard-volume ventriculography
Number of subjects: 102
Study 30613000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 436
Study 29332218 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep hygiene training (two sessions)
Number of subjects: 128
Study 29332218 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 128
Study 27450231 — intervention group
Group type: EXPERIMENTAL
Intervention: Greenselect Phytosome® (150 mg/dose) and piperine (15 mg/dose)
Number of subjects: 40
Study 27450231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25368724 — intervention group
Group type: EXPERIMENTAL
Intervention: IvIg (0.4 g/kg/day for 5 days)
Number of subjects: 41
Study 25368724 — intervention group
Group type: COMPARATOR
Intervention: PE (4 PE during 10-14 days)
Number of subjects: 41
Study 23469601 — intervention group
Group type: EXPERIMENTAL
Intervention: Qiyao Xiaoke Capsule (QXC), 0.4 g/pill, 6 pills each time, three times a day.
Number of subjects: 116
Study 23469601 — intervention group
Group type: EXPERIMENTAL
Intervention: Qiyao Xiaoke Capsule (QXC)
Number of subjects: 116
Study 20643442 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic procedure (nonresorbable figure‐of‐8 suture placed lateral to the internal ring of the inguinal canal)
Number of subjects: 294
Study 20643442 — intervention group
Group type: COMPARATOR
Intervention: Control (no prophylactic procedure)
Number of subjects: 294
Study 19098692 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular acupuncture
Number of subjects: 144
Study 19098692 — intervention group
Group type: EXPERIMENTAL
Intervention: Periosteal acupuncture
Number of subjects: 144
Study 19098692 — intervention group
Group type: COMPARATOR
Intervention: Control group (information only)
Number of subjects: 144
Study 15837441 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme (ACE) inhibition
Number of subjects: 0
Study 11952186 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 0
Study 11952186 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 0
Study 11952186 — intervention group
Group type: COMPARATOR
Intervention: Nondepressed controls
Number of subjects: 0
Study 9449727 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective ventilation
Number of subjects: 53
Study 9449727 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 53
Study 7703650 — intervention group
Group type: EXPERIMENTAL
Intervention: Education by a trained asthma nurse
Number of subjects: 0
Study 7703650 — intervention group
Group type: COMPARATOR
Intervention: Control group (not educated by a trained asthma nurse)
Number of subjects: 0
Study 2655687 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 22
Study 2655687 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 22
Study 2655687 — intervention group
Group type: COMPARATOR
Intervention: Placebo phase
Number of subjects: 22
Study 2655687 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both agents
Number of subjects: 22
Study 1274998 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic reading instruction (parts-to-whole method)
Number of subjects: 100
Study 1274998 — intervention group
Group type: COMPARATOR
Intervention: Analytic reading instruction (whole-word method)
Number of subjects: 100
Study 30278110 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L PEGA with PLD
Number of subjects: 173
Study 30278110 — intervention group
Group type: COMPARATOR
Intervention: 2 L PEGA
Number of subjects: 173
Study 29325337 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone with ropivacaine (Group N)
Number of subjects: 70
Study 29325337 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine (Group R)
Number of subjects: 70
Study 26245675 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus Lapatinib
Number of subjects: 121
Study 26245675 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy plus Trastuzumab or Lapatinib
Number of subjects: 121
Study 26245675 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual anti-HER2 blockade (Trastuzumab and Lapatinib)
Number of subjects: 121
Study 26245675 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-gene signature analysis
Number of subjects: 121
Study 23354353 — intervention group
Group type: COMPARATOR
Intervention: Baby shampoo (Bübchen Kinder Shampoo)
Number of subjects: 53
Study 23354353 — intervention group
Group type: EXPERIMENTAL
Intervention: Phospholipid-liposome solution (Blepha Cura)
Number of subjects: 53
Study 21285986 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (D) 30 mg/m² i.v. and Epirubicin (EPI) 30 mg/m² i.v. every week (D/EPI arm)
Number of subjects: 72
Study 21285986 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (D) 70 mg/m² i.v. every 3 weeks and Prednisone (P) 5 mg twice daily (D/P arm)
Number of subjects: 72
Study 19632546 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 90
Study 19632546 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 90
Study 16396667 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin (releasing endogenous NO)
Number of subjects: 20
Study 16396667 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP, exogenous NO-donor)
Number of subjects: 20
Study 16396667 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin gene-related peptide (CGRP)
Number of subjects: 20
Study 16396667 — intervention group
Group type: COMPARATOR
Intervention: Flow-mediated dilation (FMD)
Number of subjects: 20
Study 12851532 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin bolus
Number of subjects: 206
Study 12851532 — intervention group
Group type: COMPARATOR
Intervention: No intravenous heparin bolus
Number of subjects: 206
Study 10993997 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 15
Study 10993997 — intervention group
Group type: COMPARATOR
Intervention: Clozapine
Number of subjects: 15
Study 8792695 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 290
Study 8792695 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine HCI 150 mg twice daily
Number of subjects: 290
Study 8792695 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine HCI 150 mg twice daily plus metoclopramide HCI 10 mg four times daily
Number of subjects: 290
Study 8792695 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 290
Study 8792695 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 290
Study 8792695 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine/metoclopramide
Number of subjects: 290
Study 8792695 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment (ranitidine + metoclopramide)
Number of subjects: 290
Study 1620806 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunity to release negative affect
Number of subjects: 105
Study 1620806 — intervention group
Group type: COMPARATOR
Intervention: No opportunity to release negative affect
Number of subjects: 105
Study 1620806 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger-in tendencies in women
Number of subjects: 105
Study 1620806 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger-out tendencies in women
Number of subjects: 105
Study 6332178 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose infusion methotrexate (1,500 mg/m2) with leucovorin
Number of subjects: 47
Study 6332178 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose methotrexate (40 mg/m2) without leucovorin
Number of subjects: 47
Study 6332178 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose infusion methotrexate
Number of subjects: 47
Study 6332178 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose methotrexate
Number of subjects: 47
Study 6332178 — intervention group
Group type: COMPARATOR
Intervention: High-dose infusion methotrexate and Standard-dose methotrexate
Number of subjects: 47
Study 31447547 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (90 mg/day)
Number of subjects: 60
Study 31447547 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/day)
Number of subjects: 60
Study 31447547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31447547 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan and Memantine
Number of subjects: 60
Study 30181110 — intervention group
Group type: EXPERIMENTAL
Intervention: Siri, Alexa, or Google Assistant
Number of subjects: 54
Study 25720659 — intervention group
Group type: EXPERIMENTAL
Intervention: Biobrane(®)
Number of subjects: 28
Study 25720659 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressilk(®)
Number of subjects: 28
Study 25720659 — intervention group
Group type: COMPARATOR
Intervention: PolyMem(®)
Number of subjects: 28
Study 25243718 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Prime
Number of subjects: 125
Study 25243718 — intervention group
Group type: COMPARATOR
Intervention: No Prime
Number of subjects: 125
Study 21689317 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-guided transanal haemorrhoid dearterialization (THD)
Number of subjects: 169
Study 21689317 — intervention group
Group type: COMPARATOR
Intervention: Stapler haemorrhoidopexy (SH)
Number of subjects: 169
Study 20456300 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 83
Study 20456300 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg
Number of subjects: 83
Study 20456300 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg
Number of subjects: 83
Study 16890417 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm exercise
Number of subjects: 13
Study 16890417 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg exercise
Number of subjects: 13
Study 16251287 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleconaril
Number of subjects: 827
Study 16251287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 827
Study 11867965 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol lotion under hydrocolloid occlusion once weekly
Number of subjects: 15
Study 11867965 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol ointment twice daily
Number of subjects: 15
Study 10573105 — intervention group
Group type: EXPERIMENTAL
Intervention: MPEMi combination (Methotrexate, Cisplatin, Etoposide, Mitomycin)
Number of subjects: 101
Study 10573105 — intervention group
Group type: EXPERIMENTAL
Intervention: MPEpiE combination (Methotrexate, Cisplatin, Epirubicin, Etoposide)
Number of subjects: 101
Study 10573105 — intervention group
Group type: EXPERIMENTAL
Intervention: MPEpiV combination (Methotrexate, Cisplatin, Epirubicin, Vincristine)
Number of subjects: 101
Study 10573105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic complete response (pCR) in locally advanced disease
Number of subjects: 101
Study 9201779 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (500 mg)
Number of subjects: 10
Study 9201779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1747643 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine free diet alone
Number of subjects: 52
Study 1747643 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine free diet with caffeinated coffee
Number of subjects: 52
Study 1747643 — intervention group
Group type: COMPARATOR
Intervention: Caffeine free diet
Number of subjects: 52
Study 1747643 — intervention group
Group type: COMPARATOR
Intervention: Caffeine free diet with decaffeinated instant coffee
Number of subjects: 52
Study 1747643 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 52
Study 7116588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 10
Study 7116588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 28378441 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer and step-monitoring diary (PED)
Number of subjects: 96
Study 28378441 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer and diary plus step targets (PED+)
Number of subjects: 96
Study 28378441 — intervention group
Group type: COMPARATOR
Intervention: Education (EDUC)
Number of subjects: 96
Study 28641792 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 7141
Study 26252485 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC0109‐0012 (0.01, 0.05, 0.2, 0.6, 1.5, or 3.0 mg/kg single doses; 0.05, 0.2, 0.5, 1.0, or 2.0 mg/kg multiple doses every other week for 7 weeks; 2.0 mg/kg weekly doses for 7 weeks in expansion phase)
Number of subjects: 48
Study 26252485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 26252485 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC0109‐0012
Number of subjects: 48
Study 23723381 — intervention group
Group type: EXPERIMENTAL
Intervention: Proanthocyanidins (PA) treatment
Number of subjects: 0
Study 23723381 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 0
Study 23723381 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutaraldehyde (gold-standard cross-linker)
Number of subjects: 0
Study 19793927 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle ACL reconstruction
Number of subjects: 70
Study 19793927 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle ACL reconstruction
Number of subjects: 70
Study 18256415 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral miltefosine (2.5 mg/kg/d for 28 days)
Number of subjects: 57
Study 18256415 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular antimony (20 mg/kg/d for 20 days)
Number of subjects: 57
Study 16612915 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate (GTN) ointment, 0.2 percent, applied twice daily.
Number of subjects: 20
Study 16612915 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine, 20 mg twice daily, retard formulation.
Number of subjects: 20
Study 15322870 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptococcus pneumoniae
Number of subjects: 74
Study 15322870 — intervention group
Group type: EXPERIMENTAL
Intervention: H. influenzae
Number of subjects: 74
Study 15322870 — intervention group
Group type: EXPERIMENTAL
Intervention: M. catarrhalis
Number of subjects: 74
Study 15322870 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococci in otitis-prone children
Number of subjects: 74
Study 15322870 — intervention group
Group type: EXPERIMENTAL
Intervention: General recommendation for antimicrobial therapy
Number of subjects: 74
Study 10636106 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine preoperative ERCP
Number of subjects: 60
Study 10636106 — intervention group
Group type: COMPARATOR
Intervention: Selective postoperative ERCP
Number of subjects: 60
Study 9111852 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of individual out-patient and family treatment
Number of subjects: 0
Study 9111852 — intervention group
Group type: COMPARATOR
Intervention: Individual out-patient treatment
Number of subjects: 0
Study 8469463 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary LH assay
Number of subjects: 37
Study 8469463 — intervention group
Group type: COMPARATOR
Intervention: Traditional timing methods (cycle‐averaging and/or review of basal body temperature graphs)
Number of subjects: 37
Study 3897296 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 100 mg
Number of subjects: 210
Study 3897296 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 200 mg
Number of subjects: 210
Study 3897296 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg
Number of subjects: 210
Study 3897296 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg
Number of subjects: 210
Study 3897296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 3218878 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-group, problem-solving sessions
Number of subjects: 0
Study 3218878 — intervention group
Group type: COMPARATOR
Intervention: Traditional lectures
Number of subjects: 0
Study 3218878 — intervention group
Group type: COMPARATOR
Intervention: Large-group, case discussions
Number of subjects: 0
Study 31407484 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib sodium 40 mg before induction of anaesthesia, followed by 40 mg every 12 hours for 48 hours post-operation.
Number of subjects: 80
Study 31407484 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered 30 minutes before induction of anaesthesia, followed by placebo every 12 hours for 48 hours post-operation.
Number of subjects: 80
Study 28793834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) with good therapist fidelity
Number of subjects: 72
Study 28793834 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT) with below average therapist fidelity
Number of subjects: 72
Study 26660722 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercise with behavioural approach
Number of subjects: 216
Study 26660722 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercise without behavioural approach
Number of subjects: 216
Study 26660722 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercise (both groups combined)
Number of subjects: 216
Study 26660722 — intervention group
Group type: COMPARATOR
Intervention: Physical activity prescription
Number of subjects: 216
Study 24302679 — intervention group
Group type: EXPERIMENTAL
Intervention: High flavanol chocolate (HFC)
Number of subjects: 100
Study 24302679 — intervention group
Group type: COMPARATOR
Intervention: Normal flavanol chocolate (NFC)
Number of subjects: 100
Study 23820051 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 0
Study 23820051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23820051 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 0
Study 20140437 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 4 mg
Number of subjects: 30
Study 20140437 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 8 mg
Number of subjects: 30
Study 20140437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 27948084 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron plus dexamethasone (5 mg IV + 10 mg oral on days 1-5)
Number of subjects: 41
Study 27948084 — intervention group
Group type: COMPARATOR
Intervention: Generic ondansetron plus dexamethasone (24 mg IV + 10 mg oral on days 1-5)
Number of subjects: 41
Study 16881245 — intervention group
Group type: EXPERIMENTAL
Intervention: In Our Own Voice (IOOV) presentation
Number of subjects: 114
Study 16881245 — intervention group
Group type: COMPARATOR
Intervention: Control presentation about psychology careers
Number of subjects: 114
Study 15219521 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 0
Study 15219521 — intervention group
Group type: COMPARATOR
Intervention: Coronary bypass graft surgery
Number of subjects: 0
Study 10973155 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 CCID50
Number of subjects: 223
Study 10973155 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 CCID50
Number of subjects: 223
Study 10973155 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 CCID50
Number of subjects: 223
Study 10973155 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccine formulations
Number of subjects: 223
Study 9213829 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparansulphate 100 mg t.i.d.
Number of subjects: 30
Study 9213829 — intervention group
Group type: COMPARATOR
Intervention: Sulodexide 250 LSU b.i.d.
Number of subjects: 30
Study 8448092 — intervention group
Group type: EXPERIMENTAL
Intervention: Obturator nerve block using 5 mL of 2.0% lidocaine followed by two or three prognostic blocks using 5 mL of 0.5% bupivacaine and 1:200,000 epinephrine, and final block with 5 mL of 6.0% phenol in glycerin
Number of subjects: 0
Study 8448092 — intervention group
Group type: COMPARATOR
Intervention: Traditional approach to obturator nerve blockade
Number of subjects: 0
Study 2876772 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (C. parvum) administered intrapleurally and intravenously (7 mg injected into the pleural space and 7 mg intravenously once between days 6 and 12 postoperatively, followed by 7 mg intravenously every 3rd month during the 1st year)
Number of subjects: 286
Study 2876772 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intrapleural administration of 35 cc of saline)
Number of subjects: 286
Study 2876772 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (C. parvum)
Number of subjects: 286
Study 30661702 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50000 IU weekly for 9 weeks)
Number of subjects: 619
Study 29282609 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum (5 × 10^7 cfu g−1)
Number of subjects: 480
Study 29282609 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus bulgaricus (5 × 10^7 cfu g−1)
Number of subjects: 480
Study 29282609 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei (5 × 10^7 cfu g−1)
Number of subjects: 480
Study 29282609 — intervention group
Group type: COMPARATOR
Intervention: Control diet (without probiotics)
Number of subjects: 480
Study 27046905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic cycling
Number of subjects: 47
Study 27046905 — intervention group
Group type: COMPARATOR
Intervention: Static cycling
Number of subjects: 47
Study 25378426 — intervention group
Group type: EXPERIMENTAL
Intervention: TMSsyn group (synchronous picture-naming training with contralesional 1 Hz-rTMS for 10 daily sessions)
Number of subjects: 45